Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Industry Demands More Thinking Time On Hybrid DRGs

Minister Lauterbach wary that returning COVID-19 will get in the way of health reform plans

Executive Summary

The three-way German coalition that emerged from the 2021 general election has been steadily developing elements of its coalition agreement. A proposal on hybrid DRGs, intended to widen access to services in the outpatient sector, has prompted a white paper from industry.

You may also be interested in...



Germany’s DRG Reform Must Retain Incentives For Medtech Innovation, Says Industry

German health ministry plans to change how inpatient care is paid for and increase levels of ambulatory care have ignited a debate among industry and other stakeholders. The medtech industry gave its initial reaction to Medtech Insight.

Time is Ripe For Large-Scale German Hospital Reform – Health Ministry

DRGs are not doing what they were conceived to, ambulatory care needs more support and health care delivery across the country must be unburdened from bureaucracy, health minister Karl Lauterbach told the German hospital congress meeting during Medica 2022.

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel